Zacks Investment Research Upgrades GRIFOLS S A/S (GRFS) to Hold

Zacks Investment Research upgraded shares of GRIFOLS S A/S (NASDAQ:GRFS) from a sell rating to a hold rating in a research report report published on Wednesday.

According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “

Other analysts have also recently issued research reports about the stock. BidaskClub cut shares of GRIFOLS S A/S from a sell rating to a strong sell rating in a research report on Friday, July 13th. UBS Group cut shares of GRIFOLS S A/S from a neutral rating to a sell rating in a research report on Wednesday, October 3rd. Santander raised shares of GRIFOLS S A/S from an underperform rating to a hold rating in a research report on Tuesday, October 30th. Berenberg Bank raised shares of GRIFOLS S A/S from a hold rating to a buy rating in a research report on Thursday, October 11th. Finally, Morgan Stanley reduced their price target on shares of GRIFOLS S A/S from $22.00 to $20.00 and set an underweight rating on the stock in a research report on Monday, October 1st. Two analysts have rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the stock. The stock has an average rating of Hold and an average target price of $21.50.

GRFS stock traded down $0.03 during mid-day trading on Wednesday, hitting $21.18. 461,288 shares of the company were exchanged, compared to its average volume of 1,834,403. The company has a debt-to-equity ratio of 1.47, a current ratio of 2.78 and a quick ratio of 1.12. The firm has a market cap of $14.52 billion, a PE ratio of 19.25, a price-to-earnings-growth ratio of 1.52 and a beta of 1.18. GRIFOLS S A/S has a 12-month low of $17.47 and a 12-month high of $25.18.

The firm also recently declared a special dividend, which will be paid on Tuesday, December 11th. Stockholders of record on Monday, December 3rd will be given a dividend of $0.2283 per share. This represents a dividend yield of 2.25%. The ex-dividend date of this dividend is Friday, November 30th. This is a boost from GRIFOLS S A/S’s previous special dividend of $0.01. GRIFOLS S A/S’s dividend payout ratio is currently 35.45%.

Several institutional investors and hedge funds have recently modified their holdings of GRFS. FMR LLC lifted its position in shares of GRIFOLS S A/S by 92.1% during the third quarter. FMR LLC now owns 13,763,759 shares of the biotechnology company’s stock worth $294,132,000 after purchasing an additional 6,600,205 shares in the last quarter. SG Americas Securities LLC raised its holdings in GRIFOLS S A/S by 38,886.6% in the second quarter. SG Americas Securities LLC now owns 3,001,189 shares of the biotechnology company’s stock valued at $64,526,000 after acquiring an additional 2,993,491 shares in the last quarter. First Trust Advisors LP raised its holdings in GRIFOLS S A/S by 85.7% in the third quarter. First Trust Advisors LP now owns 4,634,749 shares of the biotechnology company’s stock valued at $99,045,000 after acquiring an additional 2,139,441 shares in the last quarter. Engadine Partners LLP raised its holdings in GRIFOLS S A/S by 18.0% in the second quarter. Engadine Partners LLP now owns 2,906,319 shares of the biotechnology company’s stock valued at $62,486,000 after acquiring an additional 443,386 shares in the last quarter. Finally, Crossmark Global Holdings Inc. acquired a new stake in GRIFOLS S A/S in the second quarter valued at approximately $7,967,000. 21.35% of the stock is currently owned by institutional investors and hedge funds.

GRIFOLS S A/S Company Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.

Recommended Story: Why do company’s buyback their stock?

Get a free copy of the Zacks research report on GRIFOLS S A/S (GRFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit